Deborah Doroshow, MD, on the Disappointments Uncovered About Inpatient Immunotherapy
Deborah Doroshow, MD, PhD, discusses a study finding that cancer patients receiving care as inpatients who start on in-patient immune checkpoint inhibitors (ICI) generally do not live long enough to benefit from the drugs.